ArticleScientific reports2019
Glandular differentiation in pT1 urothelial carcinoma of bladder predicts poor prognosis.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Prediction of recurrence using hematologic and urinary markers in intravesical Bacillus calmette Guerin treated bladder cancer.Scientific reports · 2025Article
- Frequency and Characterization of Rare Histologic Subtypes in Canine Invasive Urothelial Carcinoma.bioRxiv : the preprint server for biology · 2025Article
- Impact of variant histology in the prognosis of non‑muscle invasive bladder cancer with low‑tumor burden: A propensity score‑matched analysis with conventional urothelial carcinoma.Molecular and clinical oncology · 2024Article
- Predicting Recurrence of Non-Muscle-Invasive Bladder Cancer: Current Techniques and Future Trends.Cancers · 2022Review
- T1 bladder carcinoma with variant histology: pathological features and clinical significance.Virchows Archiv : an international journal of pathology · 2022Article
- Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies.World journal of urology · 2022Review
- Review
- Squamous or Glandular Differentiation Predicts Poor Prognosis in pT1 Urothelial Carcinoma.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the effect of glandular differentiation (GD) on tumor recurrence and progression of pT1 bladder urothelial carcinoma (UC). We performed a retrospective analysis of 82 bladder urothelial carcinoma with glandular differentiation (UCGD) patients which was pathologically diagnosed as pT1, 166 patients of pT1 UC of bladder without histologic variants served as controls. Patients of UCGD were more likely to have higher recurrence (P = 0.002) rate and higher progression rate (P < 0.001). Moreover, UCGD and a poor 5 -year overall survival (OS) (P = 0.02) while there was no difference in cancer-specific survival (CSS) (P = 0.062) between two groups. According to univariate analysis, largest tumor size (HR 1.502, CI 1.158-1.861, P = 0.029), UCGD (HR 1.787, CI 1.298-2.552, P = 0.001), lymphovascular invasion (LVI) (HR 1.226, CI 1.013-1.945, P = 0.039). UCGD (HR 1.367, CI 1.115-1.853, P = 0.038) and LVI (HR 1.416, CI 1.120-2.254, P = 0.013) were prognostic factors associated with disease recurrence and progression, respectively. Additionally, Additionally, UCGD significantly influence disease recurrence (HR 1.871, CI 1.338-2.589, P < 0.001) and progression (HR 1.462, CI 1.138-2.393, p = 0.007). Similarly, LVI significantly influence disease recurrence (HR 1.356, CI 1.053-2.174, P = 0.042) and progression (HR 1.348, CI 1.052-1.944, p = 0.022) in multivariate analysis. UCGD is significantly associated with higher recurrence and progression rate in patients with newly diagnosed pT1. Recurrent cases should be performed radical cystectomy (RC) earlier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.